REMARKS

The substitute computer readable form copy and print form copy of the Sequence Listing submitted concurrently herewith corrects errors in the original Sequence Listing per Sec. 1.823 of the New Sequence Rules that requires use of <220> to <223> features if <213>ORGANISM is "Artificial sequence". Furthermore, an additional amino acid sequence, **SEQ ID NO:53**, has been added to represent separately an amino acid sequence that was previously disclosed in **SEQ ID NO:12** in order to comply with rules of usage that require "Xaa" to represent only amino acids.

The Specification to the application has been amended to reflect the additional amino acid sequence and sequence listing identifier described above. A marked-up version of the amendments to the specification is attached hereto and is captioned "Version with Markings to Show Changes Made."

I hereby state that the content of the paper and computer readable copies of the substitute Sequence Listing, concurrently submitted to Box Sequence in accordance with 37 C.F.R. § 1.821(c) and (e), are the same and introduce no new matter.

Applicants submit that this application is in condition for substantive examination, which action is respectfully requested.

Respectfully submitted,

J. Michael Strickland
Reg. No. 47,115

USPTO CUSTOMER NO.:

20792
PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on February 10, 2003.

Monica L. Croom

Monica L. Croom

Version with Markings to Show Changes Made

In the Specification:

Please amend the paragraph beginning on page ~~25~~ 24, line ~~12~~ 28 as follows:

--(Twice amended) In another aspect, the therapeutic peptide of the amphiphilic drug-oligomer conjugates are as described in United States Patent 5,641,861, which is incorporated herein by reference, so long as any of such peptides contains a lysine residue. Exemplary peptides described therein include: Ac-Phe-Arg-Trp-Trp-Tyr-Lys—NH_2 **(SEQ ID NO:4)**; Ac-Arg-Trp-Ile-Gly-Trp-Lys—NH_2 **(SEQ ID NO:5)**; Trp-Trp-Pro-Lys-His-Xaa—NH_2 **(SEQ ID NO:6)**, where Xaa can be any one of the twenty naturally occurring amino acids, or Trp-Trp-Pro-Xaa—NH_2 **(SEQ ID NO:7)**, where Xaa is Lys or Arg; Tyr-Pro-Phe-Gly-Phe-Xaa—NH_2 **(SEQ ID NO:8)**, wherein Xaa can be any one of the twenty naturally occurring amino acids; (D)Ile-(D)Met-(D)Ser-(D)Trp-(D)Trp-Gly_n-Xaa—NH_2 **(SEQ ID NO:9)**, wherein Xaa is Gly or the D-form of a naturally-occurring amino acid and n is 0 or 1, peptides of this formula can be hexapeptides when Gly is absent (n is 0) and heptapeptides when Gly is present (n is 1); (D)Ile-(D)Met-(D)Thr-(D)Trp-Gly-Xaa—NH_2 **(SEQ ID NO:10)**, wherein Xaa is Gly or the D-form of a naturally-occurring amino acid; Tyr-A1-B2-C3—NH_2 **(SEQ ID NO:11)**, wherein A1 is (D)Nve or (D)Nle, B2 is Gly, Phe, or Trp, and C3 is Trp or Nap; Pm and red {Me_xH_yN-Tyr-$(NMe)_{[z]}$-Tyr-Xaa—NH_2} **(SEQ ID NO:12)**, wherein x and y independently are 0,1, or 2 and z is 0 or 1, and wherein Xaa is Phe**[**,**]** or D-Phe**[, or NHBzl]**; Pm and red {Me_xH_yN-Tyr-(NMe)-Tyr-Xaa—NHBzl} **(SEQ ID NO:53)**, wherein x and y independently are 0,1, or 2 and z is 0 or 1, and wherein Xaa is Phe or D-Phe; Trp-Trp-Pro-D4-His_z-Xaa_z-NH_2 **(SEQ ID NO:13)**, wherein z is 0 or 1, D4 is Lys or Arg and Xaa is any one of the naturally-occurring amino acids.--

* * * *END* * * *